| Sickle Cell Anemia |
1 |
1 |
| Genomic Medicine |
0 |
0.81 |
| Gene Therapy |
0 |
0.99 |
| Biologic Therapy |
0 |
0.48 |
| I-Cell Disease |
0 |
0.41 |
| Lysosomal Storage Disease |
0 |
0.4 |
| Pain Management |
0 |
0.38 |
| Hospital |
0 |
0.33 |
| Pain |
0 |
0.33 |
| Adolescent Medicine |
0 |
0.24 |
| Blood |
0 |
0.24 |
| Gene Editing |
0 |
0.24 |
| Hemoglobin |
0 |
0.24 |
| Cerebrovascular Accident |
0 |
0.22 |
| Anaphylaxis |
0 |
0.17 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.17 |
| Stem Cell Research and Therapy |
0 |
0.17 |
| Graft |
0 |
0.16 |
| Liver Disease |
0 |
0.12 |
| Alabama |
0 |
0.08 |
| Cerebrovascular Accident History |
0 |
0.08 |
| Child |
0 |
0.08 |
| CRISPR |
0 |
0.08 |
| Fatigue |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Hematology |
0 |
0.08 |
| Inpatient Care |
0 |
0.08 |
| Interference |
0 |
0.08 |
| Liver |
0 |
0.08 |
| Michigan |
0 |
0.08 |
| Ohio |
0 |
0.08 |
| Patient History |
0 |
0.08 |
| Remission |
0 |
0.08 |
| Tissue |
0 |
0.08 |
| Transfusion |
0 |
0.08 |